Durvalumab after chemoradiotherapy in limited stage small cell lung cancer.

Trial Identifier: D419QL00009
Sponsor: AstraZeneca
Start Date: September 2025
Primary Completion Date: June 2029
Study Completion Date: June 2029
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES A Coruña, ES, 15006
ES Badajoz, ES, 06080
ES Barakaldo, ES, 48903
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Barcelona, ES, 08907
ES Jerez de la Frontera, ES, 11407
ES Madrid, ES, 28046
ES Madrid, ES, 28041
ES Málaga, ES, 29010
ES Oviedo, ES, 33011
ES Santander, ES, 39008
ES Sevilla, ES, 41013
ES Valencia, ES, 46026
ES Zaragoza, ES, 50009